Capricor Therapeutics (CAPR) Cash from Investing Activities (2011 - 2026)

Capricor Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$154.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 747.29% year-over-year to -$154.6 million; the TTM figure through Mar 2026 stood at -$81.1 million (up 2.1% YoY), while the FY2025 annual figure was $97.5 million, up 183.9% from the prior year.
• Cash from Investing Activities was -$154.6 million for Q1 2026 at Capricor Therapeutics, down from $43.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $43.1 million in Q4 2025 to a low of -$154.6 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$12.0 million across 5 years, with a median of $2.0 million in 2024.
• Biggest YoY gain for Cash from Investing Activities was 1494.77% in 2022; the steepest drop was 10882.05% in 2022.
• A 5-year view of Cash from Investing Activities shows it stood at $5.1 million in 2022, then sank by 214.01% to -$5.9 million in 2023, then plunged by 2004.53% to -$123.4 million in 2024, then surged by 134.92% to $43.1 million in 2025, then tumbled by 458.89% to -$154.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$154.6 million (Q1 2026), $43.1 million (Q4 2025), and $16.0 million (Q3 2025), per Business Quant data.